viral hepatitis-oncogenic mechanisms of the virus hans peter dienes medical university of vienna
TRANSCRIPT
HCC – The Facts
• Second most frequent cancer related cause of death• Rapid increase in most Western countries; • >90% defined etiology; linked to chronic liver disease and
chronically damaged non-tumorous liver (~90%); epidemiology linked to prevalence of underlying diseases
• Incidence increases with time and duration of chronic liver disease
• Paradigm of viral, metabolic and inflammation induced cancer
Chronic Inflammation and Cancer
• Viral hepatitis – HCC• Steatohepatitis – HCC• Colitis ulcerosa – CRC• PSC – CC• Chronic gastritis (Type B) – Gastric cancer, MALT Lymphoma• Chronic urocystitis – bladder cancer• Chronic pancreatitis – pancreatic cancer
Variable frequency argues for mixed/heterogenous mechanisms
How is Chronic Inflammation linked to Cancer?
• Etiology of inflammation also causes cancer by independent mechanisms
• (Necro-)Inflammation itself is oncogenic– Inflammatory cytokines– Direct cellular response
• Consequences of (necro-) inflammation are oncogenic– Stochastic effects of cellular turnover/repair– Wound healing effects (fibrosis
chronic
liver
damage
chronic viral hepa- titis
genetic
disorders
chronic alcohol abuseNASH
fibrosis
large cell dys- plasia
smallcellproli-feration
dedifferentiation oforiginal hepatocytes?
stem cellactivation?
dys-plasticfoci
dysplasticnodule(low grade)
dysplasticnodule(high grade)
borderline lesions
mal
igna
nttr
ansf
orm
ation
cirrhosis
early
HCC
fullydeve-lopedHCC
tumor
growth
in-vasion
metas- tasis
focu
s fo
rmati
on
size increase
t
Kern et al., Adv Cancer Res, 2002
Does Inflammation cause Liver Cancer?
Liver Fibrosis and HCC
87%
1%6%
3%3%
Stage 4
Stage 3
Stage 2
Stage 1
Stage 0
Yang JD, et al. Clin Gastroenterol Hepatol. 2011;9:64-70.
35-
40-
45-
50-
55-
60-
65-
70-
75-
80-
85+
0.0
50.0
100.0
150.0
200.0
250.0
300.0
Italy 2003 (M)Italy 2003 (F)Hong Kong 2006 (M) Hong Kong 2006 (F) Sweden 2005 (M) Sweden 2005 (F)
HCC increases with age
HCC has Defined Etiology(Regensburg; Germany; n=374)
Int J Clin Exp Med. 2010; 3(2): 169–179.
Prevalence in general population
Risk estimate of HCC
Current prevalence in HCC cases
Population attributable fraction
HBV 0.5-1% 20-25 10-15% 5-10%HCV 1-2% 20-25 30-60% 20-25%Alcoholic liver disease
10-15% 2-3 20-30% 20-30%
Metabolic syndrome
30-40% 1.5-2.5 20-50% 30-40%
HCC-Pathogenesis
HBV
HCV
Aflatoxins
ASH
NASH
Others
Integration
Trans-Activation
DNA-Modification
Radical Formation
Molecular Signatures
Molecular Epidemiology
Prevention
Etiology Specific Mechanism
Consequences
Diagnostics
Therapy
chromosome losses (%) gains (%)1p 15,4 5,22p 1,4 7,13p 3,9 54p 10,6 65p 1,7 13,66p 1 22,37p 0,9 158p 38 4,69p 14 3,3
10p 2,7 8,311p 5,4 4,312p 6,5 2,413p 0 014p 0 015p 0 016p 16,8 3,417p 32,1 2,918p 4,1 5,519p 6,9 520p 2 14,921p 0 022p 0 0xp 5 11,2yp 5,1 2,3
chromosome losses (%) gains (%)1q 0,6 57,12q 2,9 83q 1,9 8,84q 34,3 1,75q 7,8 11,16q 15 7,97q 3,1 16,88q 1,9 46,69q 11,1 2,9
10q 11,1 4,111q 10,2 9,412q 2,9 6,913q 26,2 7,414q 11,3 4,115q 5,4 4,616q 35,9 1,817q 3,7 22,218q 10,8 519q 3,8 10,420q 0,9 18,621q 8,8 2,222q 6,4 2,8xq 4,5 15yq 5,6 2,3
Genomic Imbalances in human HCCsGeneral analyses of genomic imbalances (n=719) HBV-specific imbalances (n=386)
HBV + HBV -
Chr. 1
Chr. 4
Moinzadeh et al., (2005) Br J Cancer
DN HCCpoorly differentiatedwell differentiated
1q+ 4q -, 13q -6p+, 8p -, 8q+, 16q -, 17p, 17q+
HBV
Cis-acting mechanisms (Integration)
Trans-acting factors (preS, X)
Necroinflammation
Oncogene activation
Suppressor inactivation
Genome destabilisation
Oncogene activation
Increased replication
Increased mutations
Cytokine induction
Oxidative stress
HBV
• Predominance of etiology-specific mechanisms (cis- and trans) of inflammatory effects
• High carcinogenicity despite low grade inflammation (tolerance/perinatal infection) and absence of cirrhosis
HBV-Oncogenic Mechanisms
• HBV DNA integrates at random sites into host genome thus inducing great genomic instabilities with loss and gains of functions
• Transgenic mice harbouring HBs and HBx develop HCC• PreS1 contains a promoter and transactivator gene• HBx protein: transactivates promoter of CREB,YAP
-suppresses p53 -activates- RAS,Raf,MAPK,PI3k,Src, wnt-cat, -NFkB,STAT3, miRNAs-26,29a,78-
88,143,602 -inhibits: miRNAs 15a, 16, 122
HBV Vaccination and HCC: Taiwan Experience
• HCC prevention extended from childhood to early adulthood• Failures: incomplete vaccination, maternal HBsAg or HBeAg
HCC in HCV - The Facts
• Prevalence of HCV+ HCC (20-90%)
• Relative Risk of HCC
– Compared to HCV - controls (25 fold)
• Absolute Risk of HCC
– HCC in HCV (1 per 100 at 30 years)
– HCC in HCV-related cirrhosis (3.5 per 100 [1-7])
HCV Cirrhosis and HCC 3% per year
HCV Cirrhosis and HCC 3% per year
Multiple smallfoci of HCCMultiple smallfoci of HCC
HCV Cirrhosis and HCC
HCV genome organization and membrane topology of cleaved viral proteins
Bartenschlager R et al., Nature Reviews 2013, 11, 482-496
HCV-Host Cell-Interaction
12 24 48 72 h
1
Infe
ctiv
ity/
ml (
log
10)
2
3
4
0
5
6
Lohmann et al., Science (1999); Wakita*, Pietschmann* et al., Nat Med (2005)
Miyanari et al., Nat Cell Biol (2007); Shavinskaya et al., JBC (2007); Appel et al., PLoS Pathog (2008)
Bartenschlager, Lohmann, Longerich
Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe. 2011 Jan 20;9(1):32-45.
HCV as the Dominant Risk Factors for HCC in the US
• HBV most frequent in Asians
• HCV most frequent in whites and blacks
• HBV most frequent in Asians
• HCV most frequent in whites and blacks
HCVHCV47%47%
HBVHBV
15%15%
BothBoth
5%5%
NeitherNeither
33%33%
(N=691)(N=691)
HCV
Viral factors Core NS5A
Necroinflammation
Oxidative stress
Metabolic changes (steatosis)
Transactivation (MAPK, AP-1)
Increased replication
Increased mutations
Cytokine induction
Oxidative stress
HCV-Oncogenic Factors
• Transgenic mice with HCV core,E1/2 develop HCC
• HCV core –ROS, suppresses p53, blocks miRNA 122
• NS 3/4A – inhibit ATM (ataxia teleangiectasia suppressor gene)—
reduced DNA repair
• NS 5A– inhibits p53, blocks TGF-β signalling HCV mutants: core-Gln
70 and NS3-Tyr 1082 are linked to HCC development,
more than infection with wild type (El-Shamy, Hepatol. 2013)
Risk Factors for HCC in Chronic HCV
– Older age– Duration of HCV infection– Male sex– Race– Alcoholism– Obesity– Diabetes– HBV co-infection– HIV co-infection– HCV RNA positive, GT1 and GT3
EntzündungRegeneration
Normale Leber
Dysplastische Foci
Dysplastische Knoten
Frühes HCC
InvasionMetastasenv
Virale Replikation Radikalbildung
Transaktivatoren Virale Integration
Tumorsuppressoren
Onkogene
Wachstumsfaktoren
Genomische Instabilität
Intrazelluläre Signalwege
Zellschaden/Zelltod
Immunreaktion
HBV HCV C2 genet. Erkr.
Stepwise Carcinogenesis
Increased Incidence of HCC in Patients Infected with Mutated HCV Strains
El-Shamy et al., Hepatology 2013,58
Animal Models for HCC
• Chimpanzees serve as models for chronic Hep. B and C however they do not develop HCC
• Woodchucks develop HCC upon infection with WHV; the DNA integrates close to c-myc gene, which is different from human disease
• Transgenic mouse models can be used to explore the oncogenicity of viral components; but different from human disease
• Chimeric mouse models are useful because they contain human hepatocytes that can be infected with HBV and HCV
HCC in a Chimeric Mouse Model
• We generated a chimeric mouse model in which transgenic SCID/Bg mice carrying the uPA (urokinase Plasminogen Activator) under the MUP (major urinary protein) received human hepatocytes and were infected after 5 weeks either with HBV or HCV. (Tesfaye, Stift,Dienes,Feinstone,‘ PloS One 2013,14,8-18).
• They developed mild hepatitis but no fibrosis or cirrhosis• After one year 21 % infected with HBV and 26% infected with
HCV developed HCCs. The HCCs originated from the human hepatocytes that were engrafted and showed histopathology identical to human HCC.
• So HBV and HCV infection can induce HCC without significant inflammation.
No significant difference between ages of encraftment, total length of timeencrafted and total length of time infected
Summary 1
• In human chronic hepatitis B and C HCC develops on the basis of chronic inflammation with fibrosis and mostly cirrhosis due to the increased and uncontrolled liver cell regeneration.
• HBV and HCV have above that direct oncogenic potential• HBV: due to the integration of viral DNA into the host genome
a great chromosomal instability is induced• HBV proteins can function as transactivators: preS1 and HBx
for CREB,YAP,RAS,Raf,wnt b-cat or suppressors: p53,miRNAs: 26,29,78,143,148
Summary 2
• HCV does not integrate its genome into the host but viral components directly act:
• HCV core inceases ROS, blocks p53,promotes ras oncogene• HCV NS3/4 blocks ATM• NS5A inhibits p53&TGF beta signalling• HCV neutralizes miRNA 122.• HCV infection with mutations in core GLN70 and NS3Tyr 1082
carries a higher risk to induce HCC than wild type HCV• Chimeric mice are an excellent model to study HCC